Nexalin technology reports results of clinical study supporting the therapeutic benefits of its gen-2, 15 milliamp neurostimulation device in treating migraine headaches and related symptoms

Houston, aug. 07, 2023 (globe newswire) -- nexalin technology, inc. (the “company” or “nexalin”) (nasdaq: nxl; nxliw) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (gen-2), 15 milliamp (ma) neurostimulation device, including the results of a study in patients with migraine headaches, which indicated a substantial and statistically significant benefit in patients.  the clinical trial was funded by the company's joint venture partner, wider come limited (“wider”), and its related companies, and was conducted at the vertigo center, department of neurology, second affiliated hospital of zhengzhou university.
NXL Ratings Summary
NXL Quant Ranking